Adamis Pharmaceuticals Co... (ADMP)
NASDAQ: ADMP
· Real-Time Price · USD
0.78
0.01 (1.50%)
At close: Sep 07, 2023, 9:59 PM
Adamis Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 12.67M | 5.12M | 5.15M | 4.85M | 1.54M | 794.89K | 4.77M | 7.72M | 12.52M | 16.06M | 15.97M |
Cost of Revenue | 4.63M | 6.28M | 6.61M | 6.28M | 5.8M | 5.38M | 8.56M | 10.74M | 11.62M | 14.04M | 14.85M |
Gross Profit | 8.04M | -1.16M | -1.46M | -1.43M | -4.25M | -4.59M | -3.8M | -3.02M | 892.35K | 2.02M | 1.12M |
Operating Income | -25.34M | -26.7M | -23.57M | -25.06M | -28.63M | -34.23M | -35.28M | -35.08M | -48.6M | -45.22M | -47.23M |
Interest Income | 14.55K | 298.83K | 314.3K | 318.44K | 318.44K | 22.25K | 6.08K | 1.93K | 1.93K | 24.04K | 40.66K |
Pretax Income | -19.07M | -23.69M | -25.02M | -26.2M | -30.61M | -31.51M | -32.48M | -37.67M | -50.23M | -52.55M | -54.49M |
Net Income | -11.56M | -16.3M | -16.13M | -26.55M | -31.92M | -39.89M | -40.8M | -45.83M | -57.42M | -52.55M | -54.5M |
Selling & General & Admin | 14.48M | 14.47M | 14.65M | 13.25M | 12.99M | 15.28M | 18.21M | 20.74M | 30.92M | 31.92M | 30.45M |
Research & Development | 2.97M | 4.53M | 7.47M | 10.38M | 11.72M | 14.36M | 13.27M | 11.31M | 10.57M | 7.65M | 8.51M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 5.01M | 5.02M | 5.03M | 5.03M | 24.09K | 16.2K |
Operating Expenses | 17.45M | 19M | 22.12M | 23.63M | 24.38M | 29.64M | 31.48M | 32.05M | 41.83M | 39.58M | 38.95M |
Interest Expense | 2.6M | 2.93M | 2.89M | 298.12K | 298.12K | 1.86K | 46.81K | 86.14K | 128.51K | 172.69K | 160.67K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 22.08M | 25.28M | 28.72M | 29.91M | 30.17M | 35.02M | 40.04M | 42.8M | 53.45M | 53.61M | 53.8M |
Income Tax Expense | -7M | -6.88M | -9.15M | -341.51K | -342.72K | 6.98M | 7.23M | 7.56M | 7.69M | 282.96K | 263.05K |
Shares Outstanding (Basic) | 7.07M | 2.57M | 2.18M | 2.14M | 2.14M | 2.14M | 2.14M | 2.13M | 2.13M | 2.13M | 1.85M |
Shares Outstanding (Diluted) | 7.07M | 2.57M | 2.18M | 2.14M | 2.14M | 2.14M | 2.14M | 2.13M | 2.13M | 2.13M | 1.85M |
EPS (Basic) | -4.85 | -6.95 | -7.53 | -12.4 | -14.93 | -18.69 | -19.15 | -22.63 | -33.7 | -34.78 | -41.08 |
EPS (Diluted) | -4.85 | -6.95 | -7.53 | -12.4 | -14.93 | -18.69 | -19.15 | -22.63 | -33.7 | -34.78 | -41.08 |
EBITDA | -15.98M | -16.65M | -20.49M | -24.65M | -27.54M | -33.82M | -34.31M | -33.36M | -38.65M | -34.35M | -34.41M |
EBIT | -23.22M | -27.51M | -14.06M | -7.63M | -11.89M | 5.03B | 5.02B | 5.01B | 5.39B | 336.68M | 318.43M |
Depreciation & Amortization | 2.31M | 3.05M | 3.33M | 1.09M | 1.77M | 822.49K | 1.13M | 1.44M | 1.99M | 3.14M | 3.34M |